Volume 4 -Issue 2 Serum Uric Acid (SUA) is an important plasma marker in patients with Coronary Heart Disease (CHD) and hypertension, which is closely related to the morbidity and mortality of Cardio Vascular Diseases (CVD) [3]. UA in the body is the final product of purine base metabolism. It is produced by hypoxanthine and xanthine via purine synthesis under the catalysis of Xanthine Oxidase (XO) [4]. The increased enzymatic activity of XO can lead to excessive accumulation of Reactive Oxygen Species (ROS), eventually causing atrial remodeling and promoting AF's occurrence [5]. The increase of

Volume 4 -Issue 2 non-complex stanford type-B AD. Many researchers advocate the use of TEVAR in treatment of acute AD, whereas some scholars believe that drug therapy should be adopted [4][5]. In this study, we investigated the long-term therapeutic effects of the two treatments and their role in suppressing the expression of inflammatory cytokines. Methods PatientsA retrospective analysis was conducted on 60 patients with acute AD admitted to the Cardiac Surgery Department of Xinjiang Uygur Autonomous Region People's Hospital from April 2016 to January 2018. The patients were divided into control group (n=30) and TEVAR group (n=30) according to different treatment methods